The intravitreal injection of Bevacizumab for retinopathy of prematurity

The intravitreal injection of Bevacizumab for retinopathy of prematurity - The intravitreal injection of Bevacizumab for ROP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028770

Enrollment

Registered

2017-08-22

Start date

2014-09-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinopathy of prematurity

Interventions

Intravitreal injection of Bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with retinopathy of prematurity in Shiga University of Medical Science Hospital. The patients who selected an intravitreal injection of Bevacizumab (IVB) after enough explanation about retina photocoagulation and IVB. Written informed consent were obtained from the patients' parents in this study.

Exclusion criteria

Exclusion criteria: The patients with systemic risk factors

Design outcomes

Primary

Measure	Time frame
Fundus examination	—

Countries

Japan

Contacts

Public ContactTomoaki Higashiyama

Shiga University of Medical Science Department of Ophthalmology

higashi@belle.shiga-med.ac.jp0775482276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026